Navigation

ExploreAnalysisInvestor RelationsAI AssistantCompareScreener
LoginSign Up FreeSign Up
PT

PTCT

Market Closed

PTC Therapeutics, Inc.

NASDAQHealthcareBiotechnology
US
991 employees
CEO: Matthew Klein
Founded: 2013
$76.82
+$0.00(+NaN%)
Market Cap
6.37B
Beta
0.53
52W Range
N/A
Dividend Yield
0.00%
OverviewForecastsFundamentalMarket SentimentValuationOwnership
OverviewForecastsFundamentalMarket SentimentValuationOwnership
Comprehensive Valuation
In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: PTCT trades 34% above its fair value of $51.99, indicating potential overvaluation despite high financial health scores and zero Monte Carlo downside risk. Conflicting valuations, notably negative DCF versus high P/E, reflect uncertainty in profitability. Elevated price implies premium valuation, increasing risk relative to fundamental value.
Enhanced Football Field Analysis
Loading comprehensive valuation data...

Fetching multi-methodology valuation ranges...

Explore PTCT

Overview

Key metrics and AI-powered insights

Forecast

Price targets and earnings estimates

Fundamentals

Income, balance sheet and cash flow

Valuation

P/E, DCF and valuation multiples

Ownership

Institutional and insider holdings

Sentiment

Analyst ratings and news sentiment

PTCT in the Healthcare

Mid Cap
Healthcare

Browse sector stocks →

Biotechnology

Browse industry stocks →

© 2026 MarketCI. All rights reserved.

HelpPricingPrivacyTerms